A photo of Phillip Minar.

Associate Professor, UC Department of Pediatrics


Board Certified

About Me


I practice pediatric gastroenterology for children, adolescents and young adults with a special focus on those who have inflammatory bowel disease (IBD). This includes Crohn’s disease and ulcerative colitis.

Our goal is to personalize IBD care and prioritize building a strong relationship with the patient and family, which includes explaining the next steps in a way that all will understand. We also strive to be very responsive to the needs of the patient and their family. I factor in how the care model will affect the patient and family and offer a positive outlook to care. My nurse team and I lead by example — we love our jobs and want our patients to see that they can have hope, even when it doesn't seem possible with a chronic illness.

The primary focus of my research is to discover novel biomarkers specific for intestinal inflammation. My colleagues and I want to develop better tools using the latest technology and research to personalize care delivery to patients with Crohn's disease and ulcerative colitis and prevent future disease-related complications.

With our previous biomarker projects, we have discovered and validated a sensitive and specific pharmacodynamic biomarker, neutrophil CD64, to objectively monitor for gut ulcerations in patients diagnosed with IBD. This biomarker is routinely used for clinical care at our center. Additionally, we have grant support to evaluate protein biomarkers in anti-TNF non-responders to better identify which patients will respond to this type of therapy.

Personally, although growing up in a family with 12 children was a wonderful experience, I am very grateful and “busy enough” keeping up with my family of four kids. Lately, I have been enjoying my Peloton bike, walks with the family, playing sports in the backyard and vacationing on a beach anywhere. I also enjoy the challenges of adventure hikes and outdoor camping, as well as coaching my kids’ sports teams. I have slowly learned to appreciate the beauty of soccer!

Research Interests

Pediatric gastroenterology; biomarkers of treatment response and disease severity in inflammatory bowel disease.

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Blog Posts

Perspective on Alternative IBD Diets

BlogRare and Complex Conditions

Perspective on Alternative IBD Diets

By Phillip Minar, MD11/4/2016

IBD: Tips for Managing Steroid Side Effects

BlogRare and Complex Conditions

IBD: Tips for Managing Steroid Side Effects

By Phillip Minar, MD7/8/2016

My Locations

My Education

BA: Duquesne University, Pittsburgh, PA.

MD: Medical College of Wisconsin, Milwaukee, WI.

Residency: Pediatrics, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, WI.

Fellowship: Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Certification: General Pediatrics; Pediatric Gastroenterology.

My Publications

Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Bauman, LE; Xiong, Y; Mizuno, T; Minar, P; Fukuda, T; Dong, M; Rosen, MJ; Vinks, AA. Inflammatory Bowel Diseases. 2020; 26:429-439.

Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab. Minar, P; Lehn, C; Tsai, Y; Jackson, K; Rosen, MJ; Denson, LA. Crohn's && Colitis 360. 2019; 1.

Implementing a Novel Quality Improvement-Based Approach to Data Quality Monitoring and Enhancement in a Multipurpose Clinical Registry. Pratt, J; Jeffers, D; King, EC; Kappelman, MD; Collins, J; Margolis, P; Baron, H; Bass, JA; Bassett, MD; Beasley, GL; et al. eGEMs. 2019; 7.

Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. Clarkston, K; Tsai, Y; Jackson, K; Rosen, MJ; Denson, LA; Minar, P. Journal of Pediatric Gastroenterology and Nutrition. 2019; 69:68-74.

Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease. Minar, P; Jackson, K; Tsai, Y; Sucharew, H; Rosen, MJ; Denson, LA. Inflammatory Bowel Diseases. 2018; 24:198-208.

Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease. Nguyen, H; Minar, P; Jackson, K; Fulkerson, PC. World Journal of Gastroenterology. 2017; 23:7644-7652.

Infliximab therapy for pediatric crohn disease and ulcerative colitis. Minar, P; Dykes, DM H; Arce-Clachar, AC; Saeed, SA. Pediatric Inflammatory Bowel Disease: Third Edition. : Springer International Publishing; Springer International Publishing; 2017.

Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients. Rosen, MJ; Karns, R; Vallance, JE; Bezold, R; Waddell, A; Collins, MH; Haberman, Y; Minar, P; Baldassano, RN; Hyams, JS; et al. Gastroenterology. 2017; 152:1345-1357.e7.

A Low Neutrophil CD64 Index Is Associated with Sustained Remission During Infliximab Maintenance Therapy. Minar, P; Jackson, K; Tsai, Y; Rosen, MJ; Northcutt, M; Khodoun, M; Finkelman, FD; Denson, LA. Inflammatory Bowel Diseases. 2016; 22:2641-2647.

Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease. Minar, P; Saeed, SA; Afreen, M; Kim, M; Denson, LA. Journal of Pediatric Gastroenterology and Nutrition. 2016; 62:715-722.